journal
MENU ▼
Read by QxMD icon Read
search

Expert Opinion on Emerging Drugs

journal
https://www.readbyqxmd.com/read/30032674/emerging-antibacterial-and-antiviral-drugs-for-treating-respiratory-tract-infections
#1
Marco Mantero, Paola Rogliani, Mario Cazzola, Francesco Blasi, Marta Di Pasquale
Management of LRTI is becoming more frequently challenging since the emergence of multidrug resistance bacteria and the increase of severe viral infection, reducing the number of available effective drugs. The clinical evaluation of new therapeutic associations is mandatory to cope with the increases in resistance, in association with better infection control and antimicrobial policies. Areas covered: We searched Pubmed in English language of phase I, II, III clinical trials and approved treatments for LRTI, between 2006 and 2016...
July 30, 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29848130/emerging-drugs-for-eosinophilic-esophagitis
#2
Robert D Pesek, Sandeep K Gupta
Eosinophilic esophagitis (EoE) is rare but incidence and prevalence is increasing. EoE is characterized by eosinophilic inflammation of the esophagus causing gastrointestinal symptoms such as abdominal pain, vomiting, reflux, dysphagia, and food impactions. If untreated, remodeling and fibrosis of the esophagus can occur and stricture formation may result. Current treatment options are limited to food-restriction diets or medications including proton pump inhibitors (PPIs) or swallowed corticosteroids. Significant progress has been made in understanding the underlying mechanisms of EoE allowing for development of drugs that target specific points in EoE pathways...
June 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29781323/targeting-the-b-cell-receptor-pathway-a-review-of-current-and-future-therapies-for-non-hodgkin-s-lymphoma
#3
Thomas D Rodgers, Patrick M Reagan
The B-cell receptor (BCR) pathway is a crucial aspect of mature lymphocytes and is maintained in B-cell neoplasms. Many small module inhibitors targeting kinases within the BCR pathway are approved, with others in development, offering alternative treatment options to standard chemoimmunotherapy. Areas covered: This review covers both approved inhibitors and investigational inhibitors of spleen tyrosine kinase (SYK), Bruton's tyrosine kinase (BTK), and phosphoinositide-3-kinase (PI3K) in the treatment of B-cell lymphomas...
June 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29737220/emerging-reverse-transcriptase-inhibitors-for-hiv-1-infection
#4
Mohammad A Rai, Sam Pannek, Carl J Fichtenbaum
There are 36.7 million people living with HIV with 20.9 million having access to antiretroviral therapy (ART). Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) remain the 'backbone' of ART. However, the currently available nine NRTIs and five non-nucleoside reverse transcriptase inhibitors (NNRTIs) have significant side effects and resistance profiles. Areas covered: We summarize the mechanisms of resistance and other limitations of the existing NRTIs/NNRTIs. GS-9131, MK-8591, Elsulfavirine and Doravirine are four new agents that are furthest along in development...
June 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29730950/emerging-intravesical-drugs-for-the-treatment-of-non-muscle-invasive-bladder-cancer
#5
Jasper Crijnen, Theo M De Reijke
Bladder cancer (BC) is a severe health burden: and has high recurrence and progression rates. Standard treatment starts with TURB followed by intravesical chemotherapy with Mitomycin C or immunotherapy with BCG. However, successful management still remains a challenge, because approximately 30% of patients have recurrence or progression within 5 years, and treatment has considerable side effects. Anticipating on the upcoming BCG shortage emphasizes, moreover, the necessity to develop and study novel treatments...
June 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29718783/an-update-on-emerging-drugs-for-the-treatment-of-idiopathic-pulmonary-fibrosis
#6
Shambhu Aryal, Steven D Nathan
Idiopathic pulmonary fibrosis is a chronic, progressive fibrotic lung disease of unknown etiology associated with a high morbidity and mortality. The hallmark of the disease is impaired healing after alveolar epithelial injury in the setting of a genetic predisposition. Development of two new drugs has changed the landscape of the treatment of IPF but more work is needed to improve outcomes and improve survival. Areas covered: The development of two antifibrotic agents, nintedanib and pirfenidone has been an exciting landmark in the treatment of IPF...
June 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29638150/emerging-drugs-for-primary-progressive-multiple-sclerosis
#7
Ram Narendra Narayan, Thomas Forsthuber, Olaf Stüve
The identification of effective therapies for progressive forms of multiple sclerosis (MS) has remains a priority and challenge for the global MS community. Despite a few proposed mechanisms, a more complete understanding of the mechanisms involved in the pathogenesis of these MS phenotypes, animal models that incorporate these pathogenic characteristics, novel trial designs, drug repurposing strategies, and new models of collaboration between clinical and basic science personnel may be required in identifying effective therapies...
June 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29595348/parp-inhibitors-for-homologous-recombination-deficient-prostate-cancer
#8
Eric S Christenson, Emmanuel S Antonarakis
Prostate adenocarcinoma represents a leading cause of cancer-related mortality. Increased emphasis on understanding the molecular basis of prostate cancer has identified a substantial burden of homologous recombination (HR) pathway mutations, which are enriched in castrate-resistant disease. This discovery has yielded novel therapeutic opportunities. Areas covered: We will discuss the treatment of castrate-resistant prostate cancer (CRPC), with a focus on the use of poly (ADP-ribose) polymerase (PARP) inhibitors in this space...
June 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29528256/emerging-growth-factor-receptor-antagonists-for-ovarian-cancer-treatment
#9
REVIEW
Luisa Bonilla, Amit Oza, Stephanie Lheureux
Epithelial Ovarian Cancer (EOC) is the most lethal gynecological malignancy. EOC outcomes remain unsatisfactory despite aggressive surgical approach, disease chemo-sensitivity and recent introduction of agents targeting angiogenesis and tumour genome instability. Advances in EOC research have allowed for a tailored treatment approach and accelerated development of novel treatments strategies from bench to bed side, anticipated to improve patient outcomes. Areas covered: Comprehensive review of growth factor receptor antagonists for EOC treatment currently in different stages of development was performed...
March 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29508636/emerging-pharmacotherapies-for-the-treatment-of-atrial-fibrillation
#10
REVIEW
Alessandro Capucci, Laura Cipolletta, Federico Guerra, Irene Giannini
The main aim of current research on the field of atrial fibrillation (AF) treatment is to find new antiarrhythmic drugs with less side effects. Areas covered: Dronedarone and vernakalant showed promising result in term of efficacy and safety in selected patients. Ranolazine and colchicine are obtaining a role as a potential antiarrhythmic drug. Ivabradine is used in experimental studies for the rate control of AF. Moreover, new compounds (vanoxerine, moxonidine, budiodarone) are still under investigation. Monoclonal antibodies or selective antagonist of potassium channel are under investigation for long term maintenance of sinus rhythm...
March 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29486606/emerging-treatment-options-for-uterine-fibroids
#11
REVIEW
Jacques Donnez, Pablo Arriagada, Olivier Donnez, Marie-Madeleine Dolmans
Uterine fibroids (also known as leiomyomas or myomas) are the most common form of benign uterine tumors. Current management strategies involve mainly surgical interventions, but the choice of treatment is guided by patient age and desire to preserve fertility or avoid 'radical' surgery such as hysterectomy. Areas covered: There is growing evidence of the crucial role of progesterone pathways in the pathophysiology of uterine fibroids, leading to increasing use of selective progesterone receptor modulators (SPRMs) such as ulipristal acetate...
March 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29480036/emerging-drugs-for-the-treatment-of-myelofibrosis
#12
REVIEW
Aditya Shreenivas, John Mascarenhas
Myelofibrosis (MF) is a Philadelphia chromosome-negative myeloproliferative neoplasm (MPN). It can be sub-categorized into primary myelofibrosis, post polycythemia vera myelofibrosis and post essential thrombocythemia myelofibrosis. MF is a life-threatening hematologic malignancy characterized by dysregulation of the Janus associated kinase (JAK)/signal transducer and activator of transcription (STAT) signaling network and a heightened inflammatory state. Areas covered: We cover the pathogenesis, clinical features, new prognostic models, current treatment of MF and discuss agents in development...
March 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29480034/emerging-alternatives-to-tyrosine-kinase-inhibitors-for-treating-chronic-myeloid-leukemia
#13
REVIEW
Simon Kavanagh, Aisling Nee, Jeffrey H Lipton
BCR-ABL-directed tyrosine kinase inhibitors (TKIs) have revolutionised therapy for chronic myeloid leukemia. However, despite the availability and efficacy of this class of agents, lifelong treatment is still required in a significant proportion of patients Areas covered: We give an overview of the currently available BCR-ABL-directed TKIs and other conventional therapies for CML. We proceed to review the current market and some of the scientific rationale for new drug development before outlining a number of novel therapies, considered broadly as immunotherapies and targeted agents...
March 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29475394/emerging-drugs-for-the-treatment-of-axial-spondyloarthritis
#14
REVIEW
Judith Rademacher, Denis Poddubnyy
The treatment of axial spondyloarthritis(axSpA) has been for nearly 15 years constricted to non-steroidal antirheumatic drugs and TNFα inhibitors. With the approval of secukinumab, a drug targeting the interleukin(IL)-17 axis became available. Nonetheless, an unmet need for further emerging therapeutic options remains. Areas covered: This review summarizes the recent and ongoing clinical trials with novel drugs in axSpA. Besides secukinumab, further therapeutics directed against the IL-17A (e.g. ixekizumab) as well as the dual IL-17A and F inhibitor bimekizumab and the IL-17RA antibody brodalumab are in development...
March 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29468924/emerging-molecular-target-antagonists-for-the-treatment-of-biliary-tract-cancer
#15
REVIEW
Pasquale Lombardi, Donatella Marino, Elisabetta Fenocchio, Giovanna Chilà, Massimo Aglietta, Francesco Leone
Biliary tract cancers (BTCs) are a heterogeneous group of cancers, characterized by low incidence but poor prognosis. Even after complete surgical resection for early stage, relapse is frequent and the lack of effective treatments contributes to the dismal prognosis. To date, the only standard treatment in first-line is cisplatin/gemcitabine combination, whereas no standard in 2nd-line has been defined. Hence, the current goal is to better understand the biology of BTCs, discovering new treatment methods and improving clinical outcomes...
March 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29466675/emerging-drugs-for-alopecia-areata-jak-inhibitors
#16
REVIEW
Matilde Iorizzo, Antonella Tosti
Alopecia Areata is a common form of non-scarring hair loss that usually starts abruptly with a very high psychological impact. Due to the still not completely understood etiopathogenesis, at present there is no treatment that can induce a permanent remission and there is no drug approved for the treatment of this disorder. Areas covered: Leading existing treatment are briefly overviewed and then ongoing research on Janus Kinases Inhibitors is discussed, reviewing trials with oral and topical formulations so as new opportunities for other forms of alopecia, such as cicatricial alopecia...
March 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29264936/an-update-on-new-and-emerging-therapies-for-cystic-fibrosis
#17
REVIEW
Kristin M Hudock, John Paul Clancy
Cystic fibrosis (CF) is a genetic disorder that results in a multi-organ disease with progressive respiratory decline that ultimately leads to premature death. CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which codes for the CFTR anion channel. Established CF treatments target downstream manifestations of the primary genetic defect, including pulmonary and nutritional interventions. Areas covered: CFTR modulators are novel therapies that improve the function of CFTR, and have been approved in the past five years to mitigate the effects of several CF-disease causing mutations...
December 2017: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29250975/an-update-on-emerging-drugs-for-fibromyalgia-treatment
#18
REVIEW
Fabiola Atzeni, Maria Chiara Gerardi, Ignazio Francesco Masala, Alessandra Alciati, Alberto Batticciotto, Piercarlo Sarzi-Puttini
Fibromyalgia (FM) is a chronic disorder whose symptoms of pain, fatigue, sleep disturbances and depression have a devastating effect on patients' lives as it limits their ability to engage in everyday working and social activities, and make it difficult to maintain normal relationships with family, friends and employers. None of the currently available drugs are fully effective against the whole spectrum of symptoms. The aim of this narrative review is to summarise the data relating to the new therapeutic options that have become available over the last few years...
December 2017: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29226734/emerging-first-line-treatment-options-for-bladder-cancer-a-review-of-phase-ii-and-iii-therapies-in-the-pipeline
#19
REVIEW
Omer Jamy, Guru Sonpavde
The treatment of urothelial carcinoma (UC) had remained unchanged for several years until the recent FDA approval of immune checkpoint inhibitors (CPIs) in the salvage setting. Novel dual CPI-CPI and CPI-chemotherapy combinations are now being investigated aggressively as first line therapy for metastatic disease. Areas covered: We discuss the recent insights into the tumor biology of UC, which may impact the prognosis as well as assist in developing precision medicine. This is followed by an overview of existing treatment including conventional chemotherapy as well as the trials that led to the recent approval of PD-1 and PD-L1 inhibitors...
December 2017: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29183145/emerging-drugs-for-the-treatment-of-gastrointestinal-stromal-tumour
#20
REVIEW
Vineela Kasireddy, Margaret von Mehren
Tyrosine kinase inhibitors (TKIs) have transformed the treatment landscape for patients with gastrointestinal stromal tumors (GIST). Unfortunately, resistance to the currently approved TKIs poses a huge challenge, and patients are in need of additional therapeutic options. Fortunately, many novel therapeutic approaches are being tested in treatment of GIST to overcome resistance to the approved TKIs Areas covered: We performed an extensive literature (PUBMED) search to identify emerging drugs being tested in treatment of GIST in early phase clinical trials...
December 2017: Expert Opinion on Emerging Drugs
journal
journal
40009
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"